Cover Image
市場調查報告書

自體免疫疾病診斷設備:醫療設備的開發平台評估

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018

出版商 GlobalData 商品編碼 351353
出版日期 內容資訊 英文 331 Pages
訂單完成後即時交付
價格
Back to Top
自體免疫疾病診斷設備:醫療設備的開發平台評估 Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018
出版日期: 2018年04月01日 內容資訊: 英文 331 Pages
簡介

本報告提供自體免疫疾病診斷設備的開發中產品相關調查,提供您各開發階段趨勢和產品的主要開發企業,現在進行中的臨床實驗,產業的最近事件等資訊。

第1章 目錄

第2章 簡介

  • 自體免疫疾病 概要

第3章 開發中的產品

  • 開發中產品:各開發階段
  • 開發中產品:地區 (國家) 別
  • 開發中產品:法規途徑別
  • 開發中產品:核准時期別 (估計)

第4章 自體免疫疾病診斷設備 - 正在開發的開發中產品:各企業

  • 開發企業 - 開發中產品:各開發階段
  • 開發中產品:各開發階段

第5章 自體免疫疾病診斷設備的開發企業與產品概要

  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc
  • Albert-Ludwigs-Universitat Freiburg
  • Alere Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Amdix B.V.
  • Analyticon Biotechnologies AG
  • apDia n.v.
  • Autoimmune Technologies, LLC
  • Beckman Coulter, Inc.
  • BG Medicine, Inc.
  • Biocortech
  • Biogen, Inc.
  • Biomedal S.L.
  • Biomerica, Inc.
  • Bionure Farma, S.L.
  • Bio-Rad Laboratories, Inc.
  • BioRap Technologies Ltd.
  • Boston University
  • CareDx, Inc.
  • CD Diagnostics, Inc.
  • Chronix Biomedical, Inc.
  • Co-Diagnostics HBDC, Inc.
  • Crescendo Bioscience, Inc.
  • Digna Biotech, S.L.
  • Durin Technologies, Inc.
  • Enterome Bioscience SA
  • Ezose Sciences Inc.
  • Flamentera AG
  • Genalyte, Inc.
  • Genentech, Inc.
  • GeNeuro SA
  • Glycominds Ltd.
  • Grifols, S.A.
  • Hannover Medical School
  • Helmholtz Centre for Infection Research
  • HOB Biotech Group Co., Ltd.
  • Hospital for Special Surgery
  • Hycor Biomedical Inc.
  • Ignyta, Inc.
  • ImmusanT, Inc.
  • Innobiochips
  • INOVA Diagnostics, Inc.
  • Institut National de la Sante et de la Recherche Medicale
  • Is Diagnostics
  • LineaGen, Inc.
  • Lophius Biosciences GmbH
  • Louisville Bioscience, Inc.
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)
  • Medica Corporation
  • Metabolomic Technologies Inc.
  • Metanomics Health GmbH
  • MSDx, Inc.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • Neuro Vigor, LLC
  • Northwestern University
  • NoToPharm s.r.l.
  • NOWDiagnostics
  • OmniBiome Therapeutics Inc.
  • One Way Liver Genomics, S.L.
  • OPKO Health, Inc.
  • Oxford Gene Technology Limited
  • Oxford Immunotec Limited
  • Pediatric Bioscience, LLC
  • Progentec Diagnostics, Inc.
  • Protagen AG
  • ProteinLogic Ltd
  • Quanterix Corporation
  • Regulus Therapeutics Inc.
  • Rice University
  • Roche Diagnostics International Ltd.
  • Shuwen Biotech Co. Ltd.
  • Singulex, Inc.
  • SomaLogic, Inc.
  • Southern Illinois University Carbondale
  • SQI Diagnostics Inc.
  • The Johns Hopkins University
  • The Walter and Eliza Hall Institute of Medical Research
  • TheraDiag SA
  • Thermo Fisher Scientific Inc.
  • Toscana Biomarkers Srl
  • Univalue Valorizacion, S.L.
  • University of California, San Francisco
  • University of Chicago
  • University of Colorado
  • University of Florida
  • University of Manchester
  • University of Oxford
  • University of Pecs
  • University Rovira i Virgili
  • US Biomarkers, Inc.
  • Washington University in St. Louis
  • XAir Diagnostics B.V.
  • XEPTAGEN SpA
  • Yale University

第6章 自體免疫疾病診斷設備 - 最近的事件

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0530EPD

GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Auto-Immune Diseases Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Auto-Immune Diseases Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Auto-Immune Diseases Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 15

2 Introduction 16

  • 2.1 Auto-Immune Diseases Overview 16

3 Products under Development 17

  • 3.1 Auto-Immune Diseases - Pipeline Products by Stage of Development 17
  • 3.2 Auto-Immune Diseases - Pipeline Products by Territory 18
  • 3.3 Auto-Immune Diseases - Pipeline Products by Regulatory Path 19
  • 3.4 Auto-Immune Diseases - Pipeline Products by Estimated Approval Date 20
  • 3.5 Auto-Immune Diseases - Ongoing Clinical Trials 21

4 Auto-Immune Diseases - Pipeline Products under Development by Companies 22

  • 4.1 Auto-Immune Diseases Companies - Pipeline Products by Stage of Development 22
  • 4.2 Auto-Immune Diseases - Pipeline Products by Stage of Development 26

5 Auto-Immune Diseases Companies and Product Overview 32

  • 5.1 Immunarray Pvt Ltd Company Overview 32
  • 5.2 Adaptive Biotechnologies Corp Company Overview 35
  • 5.3 Albert Ludwigs University of Freiburg Company Overview 37
  • 5.4 Alere Inc Company Overview 39
  • 5.5 Amarantus Diagnostics Inc Company Overview 41
  • 5.6 apDia nv Company Overview 43
  • 5.7 Autoimmune Technologies LLC Company Overview 44
  • 5.8 Beckman Coulter Inc Company Overview 48
  • 5.9 BG Medicine Inc Company Overview 49
  • 5.10 Biogen Inc Company Overview 50
  • 5.11 Biomedal SL Company Overview 51
  • 5.12 Bionure Farma SL Company Overview 53
  • 5.13 CDI Laboratories Inc Company Overview 54
  • 5.14 Chronix Biomedical Inc Company Overview 55
  • 5.15 Crescendo Bioscience Inc Company Overview 57
  • 5.16 Digna Biotech SL Company Overview 60
  • 5.17 DNAlytics Company Overview 62
  • 5.18 EMD Millipore Corp Company Overview 65
  • 5.19 Enable Biosciences Inc Company Overview 66
  • 5.20 Enterome Bioscience SA Company Overview 67
  • 5.21 Ezose Sciences Inc. Company Overview 69
  • 5.22 Flamentera AG Company Overview 70
  • 5.23 Genalyte Inc Company Overview 71
  • 5.24 GeNeuro SA Company Overview 72
  • 5.25 Grifols SA Company Overview 73
  • 5.26 Hannover Medical School Company Overview 74
  • 5.27 Helmholtz Centre for Infection Research Company Overview 75
  • 5.28 HOB Biotech Group Suzhou Co Ltd Company Overview 76
  • 5.29 Hospital for Special Surgery Company Overview 77
  • 5.30 Hycor Biomedical Inc Company Overview 78
  • 5.31 Ignyta Inc Company Overview 80
  • 5.32 Immunovia AB Company Overview 82
  • 5.33 ImmusanT Inc Company Overview 84
  • 5.34 Innobiochips Company Overview 86
  • 5.35 Inova Diagnostics Inc Company Overview 87
  • 5.36 Iron Horse Diagnostics, Inc. Company Overview 91
  • 5.37 Johns Hopkins University Company Overview 93
  • 5.38 LineaGen Inc Company Overview 95
  • 5.39 Lophius Biosciences GmbH Company Overview 96
  • 5.40 Louisville Bioscience, Inc. Company Overview 97
  • 5.41 Max Delbruck Center for Molecular Medicine Company Overview 100
  • 5.42 Medica Corp Company Overview 101
  • 5.43 Metabiomics Corporation Company Overview 103
  • 5.44 Metabolomic Technologies Inc Company Overview 105
  • 5.45 Metanomics Health GmbH Company Overview 108
  • 5.46 MSDx Inc Company Overview 109
  • 5.47 Myriad Genetics Inc Company Overview 110
  • 5.48 Nanosphere Inc Company Overview 111
  • 5.49 Neuro Vigor LLC Company Overview 112
  • 5.50 Northwestern University Company Overview 113
  • 5.51 NoToPharm srl Company Overview 114
  • 5.52 Numares AG Company Overview 119
  • 5.53 OmniBiome Therapeutics Inc Company Overview 120
  • 5.54 One Way Liver SL Company Overview 121
  • 5.55 OPKO Health Inc Company Overview 122
  • 5.56 Oxford Gene Technology Ltd Company Overview 123
  • 5.57 Oxford Immunotec Ltd Company Overview 124
  • 5.58 Pediatric Bioscience, LLC Company Overview 125
  • 5.59 Progentec Diagnostics, Inc. Company Overview 126
  • 5.60 Protagen AG Company Overview 127
  • 5.61 ProteinLogic Ltd Company Overview 131
  • 5.62 Quanterix Corp Company Overview 132
  • 5.63 Rambam Health Care Campus Company Overview 133
  • 5.64 Rappaport Family Institute for Research in the Medical Science Company Overview 134
  • 5.65 Regulus Therapeutics Inc Company Overview 135
  • 5.66 Roche Diagnostics International Ltd Company Overview 136
  • 5.67 Seattle Children's Hospital Company Overview 140
  • 5.68 Sengenics International Pte Ltd Company Overview 141
  • 5.69 Sequenom Inc Company Overview 143
  • 5.70 Shuwen Biotech Co Ltd Company Overview 144
  • 5.71 SomaLogic Inc Company Overview 145
  • 5.72 Southern Illinois University Carbondale Company Overview 146
  • 5.73 SQI Diagnostics Inc Company Overview 148
  • 5.74 Statens Serum Institut Company Overview 153
  • 5.75 TBG Diagnostics Ltd Company Overview 154
  • 5.76 The Walter and Eliza Hall Institute of Medical Research Company Overview 155
  • 5.77 Thermo Fisher Scientific Inc Company Overview 156
  • 5.78 Toscana Biomarkers Srl Company Overview 170
  • 5.79 University Health Network Company Overview 173
  • 5.80 University of California San Francisco Company Overview 174
  • 5.81 University of Chicago Company Overview 175
  • 5.82 University of Colorado Company Overview 176
  • 5.83 University of Houston Company Overview 177
  • 5.84 University of Illinois at Chicago Company Overview 178
  • 5.85 University of Manchester Company Overview 179
  • 5.86 University of Maryland Baltimore Company Overview 181
  • 5.87 University of Missouri Company Overview 182
  • 5.88 University of Oxford Company Overview 183
  • 5.89 University of Pecs Company Overview 185
  • 5.90 University of Southern California Company Overview 186
  • 5.91 University Rovira i Virgili Company Overview 187
  • 5.92 US Biomarkers Inc Company Overview 188
  • 5.93 Washington University in St Louis Company Overview 189
  • 5.94 XEPTAGEN SpA Company Overview 190
  • 5.95 Yale University Company Overview 191

6 Auto-Immune Diseases- Recent Developments 192

  • 6.1 Mar 16, 2018: Thermo Fisher Scientific Announces Plans to Build State-Of-The-Art Pharma Services Facility in Rheinfelden 192
  • 6.2 Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 192
  • 6.3 Mar 07, 2018: Trinity Biotech announces Quarter 4 and Fiscal Year 2017 Financial Results 193
  • 6.4 Mar 01, 2018: OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results 196
  • 6.5 Mar 01, 2018: Oxford Immunotec Announces Appointment of Mark Klausner to the Board of Directors 197
  • 6.6 Feb 27, 2018: Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results 198
  • 6.7 Feb 27, 2018: Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results 200
  • 6.8 Feb 20, 2018: Theradiag Announces 2017 Annual Sales and Cash Flow at End 2017 201
  • 6.9 Feb 15, 2018: Immunovia Full Year report, January-December 2017 202
  • 6.10 Feb 13, 2018: Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors 203
  • 6.11 Feb 12, 2018: Luminex Reports Fourth Quarter and Full-Year 2017 Financial Results 203
  • 6.12 Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 204
  • 6.13 Feb 05, 2018: CyPass Ushers in Exciting New Era of Glaucoma Treatment 205
  • 6.14 Feb 05, 2018: SQI Diagnostics Reports First Quarter 2018 Results 206
  • 6.15 Jan 31, 2018: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2017 Results 207
  • 6.16 Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 209
  • 6.17 Jan 31, 2018: Thermo Fisher Scientific Uses Tax Reform Benefit to Make Additional Investments in Colleagues, Customers and Communities 214
  • 6.18 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics 215
  • 6.19 Jan 26, 2018: OPKO Health Announces Resignation Of Gregory Henderson As President Of BioReference Laboratories 215
  • 6.20 Jan 24, 2018: Genalyte Receives ISO 13485 Medical Device Manufacturing Certification 215
  • 6.21 Jan 16, 2018: Avi Pelossof Appointed President and CEO of Immucor 216
  • 6.22 Jan 16, 2018: Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter 216
  • 6.23 Jan 08, 2018: CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 217
  • 6.24 Jan 03, 2018: Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test 217
  • 6.25 Jan 03, 2018: Genalyte to Offer Patient Testing & Demonstration of its Diagnostic Cloud Lab in San Francisco January 7-11 218

7 Appendix 326

  • 7.1 Methodology 326
  • 7.2 About GlobalData 329
  • 7.3 Contact Us 329
  • 7.4 Disclaimer 329

List of Tables

1.1 List of Tables

  • Table 1: Auto-Immune Diseases - Pipeline Products by Stage of Development 19
  • Table 2: Auto-Immune Diseases - Pipeline Products by Territory 20
  • Table 3: Auto-Immune Diseases - Pipeline Products by Regulatory Path 21
  • Table 4: Auto-Immune Diseases - Pipeline Products by Estimated Approval Date 22
  • Table 5: Auto-Immune Diseases - Ongoing Clinical Trials 23
  • Table 6: Auto-Immune Diseases Companies - Pipeline Products by Stage of Development 24
  • Table 7: Auto-Immune Diseases - Pipeline Products by Stage of Development 28
  • Table 8: Immunarray Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 9: SLE-Key Rule-Out Test - Product Status 34
  • Table 10: SLE-Key Rule-Out Test - Product Description 34
  • Table 11: Immunarray Pvt Ltd - Ongoing Clinical Trials Overview 35
  • Table 12: SLE-Key Rule-Out Test - Clinical Trial to Support the Clinical Implementation of ImmunArray's SLE-Key Rule-Out Test 36
  • Table 13: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 14: Non-Invasive Diagnostic Test - Celiac Disease - Product Status 37
  • Table 15: Non-Invasive Diagnostic Test - Celiac Disease - Product Description 37
  • Table 16: Pre - Symptomatic Biomarker - Type 1 Diabetes - Product Status 38
  • Table 17: Pre - Symptomatic Biomarker - Type 1 Diabetes - Product Description 38
  • Table 18: Albert Ludwigs University of Freiburg Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 19: Biomarker Based Assay - Systemic Sclerosis - Product Status 39
  • Table 20: Biomarker Based Assay - Systemic Sclerosis - Product Description 39
  • Table 21: Mitochondrial DNA Based Assay - Autoimmune and Autoinflammatory Diseases - Product Status 40
  • Table 22: Mitochondrial DNA Based Assay - Autoimmune and Autoinflammatory Diseases - Product Description 40
  • Table 23: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 24: AIMS System - Cardiolipin IgG Test - Product Status 41
  • Table 25: AIMS System - Cardiolipin IgG Test - Product Description 41
  • Table 26: AtheNA Multi-Lyte System - Cardiolipin IgG Test - Product Status 42
  • Table 27: AtheNA Multi-Lyte System - Cardiolipin IgG Test - Product Description 42
  • Table 28: Amarantus Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 29: Diagnostic Assay - Neuromyelitis Optica - Product Status 43
  • Table 30: Diagnostic Assay - Neuromyelitis Optica - Product Description 43
  • Table 31: Diagnostic Assay - Paraneoplastic Disease - Product Status 44
  • Table 32: Diagnostic Assay - Paraneoplastic Disease - Product Description 44
  • Table 33: apDia nv Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 34: Diagnostic Test - MS (Multiple Sclerosis) - Product Status 45
  • Table 35: Diagnostic Test - MS (Multiple Sclerosis) - Product Description 45
  • Table 36: Autoimmune Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 37: Anti-Squalene Antibody Assay - Product Status 46
  • Table 38: Anti-Squalene Antibody Assay - Product Description 46
  • Table 39: Autoimmune Disease Virus Assay - Graves' Disease - Product Status 47
  • Table 40: Autoimmune Disease Virus Assay - Graves' Disease - Product Description 47
  • Table 41: Autoimmune Disease Virus Assay - Juvenile Rheumatoid Arthritis - Product Status 47
  • Table 42: Autoimmune Disease Virus Assay - Juvenile Rheumatoid Arthritis - Product Description 48
  • Table 43: Autoimmune Disease Virus Assay - Sjogren Syndrome - Product Status 48
  • Table 44: Autoimmune Disease Virus Assay - Sjogren Syndrome - Product Description 48
  • Table 45: Autoimmune Disease Virus Assay - Systemic Lupus Erythematosus - Product Status 49
  • Table 46: Autoimmune Disease Virus Assay - Systemic Lupus Erythematosus - Product Description 49
  • Table 47: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 48: SYNCHRON LXi 725 Anti-dsDNA Assay - Product Status 50
  • Table 49: SYNCHRON LXi 725 Anti-dsDNA Assay - Product Description 50
  • Table 50: BG Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 51: Diagnostic Assay - Multiple Sclerosis - Product Status 51
  • Table 52: Diagnostic Assay - Multiple Sclerosis - Product Description 51
  • Table 53: Biogen Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 54: Companion Diagnostic Test - Sjogren's Syndrome - Product Status 52
  • Table 55: Companion Diagnostic Test - Sjogren's Syndrome - Product Description 52
  • Table 56: Biomedal SL Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 57: ELISA DELIAC GFD - Product Status 53
  • Table 58: ELISA DELIAC GFD - Product Description 53
  • Table 59: IVYLISA DGP8 - Product Status 54
  • Table 60: IVYLISA DGP8 - Product Description 54
  • Table 61: Stick DELIAC GFD - Product Status 54
  • Table 62: Stick DELIAC GFD - Product Description 54
  • Table 63: Bionure Farma SL Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 64: BN - 301 Diagnostic/Prognostic Test - Product Status 55
  • Table 65: BN - 301 Diagnostic/Prognostic Test - Product Description 55
  • Table 66: CDI Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 67: Diagnostic Test - Systemic Lupus Erythematosus - Product Status 56
  • Table 68: Diagnostic Test - Systemic Lupus Erythematosus - Product Description 56
  • Table 69: Chronix Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 70: Companion Diagnostic Test - Multiple Sclerosis - Product Status 57
  • Table 71: Companion Diagnostic Test - Multiple Sclerosis - Product Description 57
  • Table 72: Diagnostic Test - Systemic Lupus Erythematous - Product Status 58
  • Table 73: Diagnostic Test - Systemic Lupus Erythematous - Product Description 58
  • Table 74: Crescendo Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 75: Multi-Biomarker Test - Ankylosing Spondylitis - Product Status 59
  • Table 76: Multi-Biomarker Test - Ankylosing Spondylitis - Product Description 59
  • Table 77: Multi-Biomarker Test - Autoimmune Diseases - Product Status 60
  • Table 78: Multi-Biomarker Test - Autoimmune Diseases - Product Description 60
  • Table 79: Multi-Biomarker Test - Psoriatic Arthritis - Product Status 60
  • Table 80: Multi-Biomarker Test - Psoriatic Arthritis - Product Description 60
  • Table 81: Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Status 61
  • Table 82: Multi-Biomarker Test - Systemic Lupus Erythematosus - Product Description 61
  • Table 83: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 84: Anti-CD-137 Antibodies Assay - Product Status 62
  • Table 85: Anti-CD-137 Antibodies Assay - Product Description 62
  • Table 86: Prognostic Test - Multiple Sclerosis - Product Status 63
  • Table 87: Prognostic Test - Multiple Sclerosis - Product Description 63
  • Table 88: DNAlytics Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 89: RheumaKit-Tx - Product Status 64
  • Table 90: RheumaKit-Tx - Product Description 64
  • Table 91: DNAlytics - Ongoing Clinical Trials Overview 65
  • Table 92: RheumaKit-Tx - Prediction of the Response to Anti-TNFs DMARDs Based on the RheumaKit Platform (RK-Tx-01) 66
  • Table 93: EMD Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 94: Erenna IL-12 Immunoassay Kit - Product Status 67
  • Table 95: Erenna IL-12 Immunoassay Kit - Product Description 67
  • Table 96: Enable Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 97: ADAP Autoimmune Disease Assay - Product Status 68
  • Table 98: ADAP Autoimmune Disease Assay - Product Description 68
  • Table 99: Enterome Bioscience SA Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 100: Diagnostic Test - Multiple Sclerosis - Product Status 69
  • Table 101: Diagnostic Test - Multiple Sclerosis - Product Description 69
  • Table 102: Diagnostic Test - Type 2 Diabetes - Product Status 70
  • Table 103: Diagnostic Test - Type 2 Diabetes - Product Description 70
  • Table 104: Ezose Sciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 105: Biomarker Diagnostic Assay - Multiple Sclerosis - Product Status 71
  • Table 106: Biomarker Diagnostic Assay - Multiple Sclerosis - Product Description 71
  • Table 107: Flamentera AG Pipeline Products & Ongoing Clinical Trials Overview 72

List of Figures

1.2 List of Figures

  • Figure 1: Auto-Immune Diseases - Pipeline Products by Stage of Development 19
  • Figure 2: Auto-Immune Diseases - Pipeline Products by Territory 20
  • Figure 3: Auto-Immune Diseases - Pipeline Products by Regulatory Path 21
  • Figure 4: Auto-Immune Diseases - Pipeline Products by Estimated Approval Date 22
  • Figure 5: Auto-Immune Diseases - Ongoing Clinical Trials 23
Back to Top